Teleflex Incorporated (TFX) Earnings Call Transcript & Summary

May 1, 2025

New York Stock Exchange US Health Care Health Care Equipment and Supplies earnings 61 min

Earnings Call Speaker Segments

Lawrence Keusch

executive
#1

Good morning, everyone, and thank you for being here on today's call as we discuss Teleflex Incorporated's first quarter 2025 results. Our website, teleflex.com, has both the press release and the accompanying slides available for you. Also, please note that a replay will be posted on our site — the press release we issued earlier today contains everything you need to know if you'd like to access it. Joining us this morning are Liam Kelly, our Chairman, President, and Chief Executive Officer, along with John Deren, Executive Vice President and Chief Financial Officer. Liam and John will each deliver prepared comments, and following that, we'll move into the Q&A portion. At the outset, please note that during this call, some topics we cover will contain predictions regarding upcoming occurrences, which are outlined in the presentation available on Teleflex's Investor Relations webpage. We'd like to warn you that such remarks are indeed anticipatory and carry potential hazards and unknowns, so real outcomes or developments could vary significantly. Several elements might lead real outcomes or occurrences to diverge significantly from expectations. These encompass, though they aren't restricted to, the items we cited in today's press release and the documents we've submitted to the SEC — among them our Form 10-K, which you can find on our site. At this point, I'll hand things over to Liam so he can share his comments.

Liam Kelly

executive
#2

Thanks, Larry, and good morning to all of you. During today's call, we'll go over the Q1 results, walk through strategic and commercial highlights, and give an update on our financial guidance for 2025. In Q1, Teleflex revenues came in at $700.7 million, a 5% decline versus the prior year on a GAAP basis, and a 3.8% drop on an adjusted constant currency basis, which fell inside the minus 3% to minus 4% guidance range we shared on our Q4 earnings call. Revenues landed $2 million under the midpoint of that range because of some order softness in EMEA, which has recovered since April. Q1 adjusted earnings per share came to $2.91, down 9.3% versus the prior year. Now let's take a closer look at our Q1 revenue results. I'll start by reviewing our geographic segment revenues for Q1. Unless I note otherwise, all growth rates I mention are on an adjusted constant currency basis. Americas revenues were $475.7 million, down 3.2% versus the prior year. Revenue growth in the quarter matched expectations and was affected by OEM declines and ongoing challenges in the UroLift office site of service. EMEA revenues of $151.2 million fell 2.8% versus the prior year. Strong performance in surgical and vascular access was largely offset by anesthesia. We saw lower-than-expected orders during the latter part of Q1, which have recovered in April. Turning to Asia, revenues were $73.8 million, down 9.7% versus the prior year and in line with our expectations. Revenue growth was affected by the previously announced volume-based procurement in our China business. We expect sequential quarterly revenue improvement in our China business through the remainder of 2025. Let's now discuss our Q1 revenues by global product category. Commentary on global product category growth for Q1 will also be on a year-over-year adjusted constant currency basis. Starting with vascular access, revenue rose 1.9% versus the prior year to $182.4 million. The quarter was led by year-over-year growth in PICCs, which increased at a double-digit rate, and a solid performance in EZ-IO. We still expect our vascular access business to grow in the mid-single-digit range in 2025, driven by continued PICC growth and the return of the Endurance Catheter to the market. Moving to interventional, revenue was $137.5 million, up 3.2% versus the prior year. During the quarter, performance was led by growth drivers such as Complex Catheters; in the quarter, we continued to see robust demand for intra-aortic balloon pumps, which grew at a strong double-digit rate in the Americas, offset by a tough year-over-year comp in Asia. Turning to anesthesia, revenue fell 8.6% versus the prior year to $86.6 million. Among our largest product categories, endotracheal tubes and hemostatic products showed growth in the quarter and were primarily offset by a tough comp in military orders and pressure on airway products. In our surgical business, revenue was $105.8 million, up 2% versus the prior year. The fundamentals of our main surgical business remain stable, though China's volume-based procurement is having the anticipated effect and partly offsets that strength. Interventional urology brought in $71 million in revenue, which is a 10.7% decline compared to the same period last year. Barrigel delivered strong double-digit growth, but UroLift keeps facing headwinds, especially in the office site of service. OEM revenue came in at $63.9 million, down 26.8% from a year earlier. This matched what we had anticipated. Results for the quarter reflected the last customer contract we talked about on our Q3 of 2024 call, while the rest stemmed from customer inventory management. As anticipated, that last customer contract reduced Q1 revenue by roughly $7 million, with customer inventory management accounting for the remainder. Specifically, as the quarter went on, we started to observe the anticipated uptick in order rates from our customers, which confirms our belief that growth would improve quarter over quarter as the year progressed and we hit the anniversary of losing that customer contract in the Q3 of 2025. Other revenue for Q1 rose 4.5% year-over-year to $53.5 million. That wraps up what I have to say about Q1 revenue performance. Now for a few commercial and clinical updates. Within our interventional portfolio, we are happy to report that the AC3 Range intra-aortic balloon pump has been granted 510(k) clearance by the FDA. The AC3 Range intra-aortic balloon pump is a compact device that merges the simple interface and proprietary algorithms from our flagship AC3 Optimus intra-aortic balloon pump, delivering the same precisely timed support. The AC3 Range is built to offer dependable, continuous intra-aortic balloon pump support across a range of patient transport modes, such as commonly used ground and air ambulance vehicles. The AC3 Range comes with a full-size helium tank, dual power options, and additional features that aid maneuverability. Following the FDA clearance, the AC3 Range will launch fully into the United States market and start shipping to customers in the Q2 of 2025. Additionally, in our interventional business, we shared preliminary findings from the Ringer Perfusion Balloon Catheter, or PBC catheter IDE study. The Perfusion Balloon Catheter is a rapid exchange percutaneous transluminal coronary angioplasty catheter featuring a unique helical balloon. Upon inflation, the balloon takes on a shape resembling a hollow cylinder with a large central perfusion lumen, which permits continuous coronary blood flow throughout prolonged inflations. The Ringer Perfusion Balloon Catheter study is a limited prospective multi-center single-arm IDE study conducted at four sites in the United States, gaining the Ringer Perfusion Balloon Catheter for managing emergent coronary perforations that arise during percutaneous coronary intervention procedures. The study enrolled 30 participants, and analysis was done on an intention to treat basis. The preliminary results were favorable, with the primary efficacy endpoint seen in 73% of participants, which required successful Ringer delivery and inflation at the perforation site, control of blood leakage into surrounding tissue, and preservation of antegrade coronary flow. Additionally, the data demonstrated that Ringer was delivered successfully in about 87% of the participants, and among that group, nearly 85% achieved control of blood leakage into surrounding tissue with perfusion. The purpose of these results is to support a pre-market application for a coronary perforation indication, which was submitted to the FDA not long ago. Ringer PBC holds FDA breakthrough device designation and currently carries an indication for balloon dilation of coronary artery or coronary bypass graft stenosis in cases where the physician wants distal blood perfusion during balloon inflation to improve myocardial perfusion. Then, in our emergency medicine business, QuikClot Control + has obtained FDA clearance for a broader indication covering all grades of internal and external bleeding. Together with its existing indications for severe and life-threatening bleeding, this broader indication lets us pursue more procedures for fast, effective control of bleeding that could benefit patients, clinicians, and health systems. Also, though trauma remains the primary focus for this portfolio, the broader indication will support procedures in general surgery, gynecological surgery, orthopedic surgery, and other areas as well. We estimate these additional clinical spaces contribute more than $150 million to our serviceable, addressable market in the United States. Turning to strategic updates. On February 27, we announced the intention to separate Teleflex into two independent publicly traded companies. The separation is intended to enhance value for all Teleflex shareholders.

Liam Kelly

executive
#3

Splitting things up means every company gets a strategy better suited to it, an easier operating structure, a leaner manufacturing setup, and a way of allocating capital that matches each firm's own growth approach and goals. Our view is that this proposed separation will give investors opportunities that are both more focused and distinctly attractive over the long haul; we have confidence that splitting the companies this way will let each pursue its strategic aims more successfully and generate substantial value over time for those who hold our shares. As we anticipated, once the separation was announced, a great deal of inbound interest arrived from third parties wanting to buy NewCo; our guiding aim continues to be getting the greatest possible value for shareholders. In line with that aim, and with the board fully backing and supervising the process, management keeps actively examining every option, among them a possible sale of NewCo running alongside the possible spin. We will keep the investment community posted on how things develop, as seems fitting, while we work through these two tracks at once; our attention stays fixed on execution, and we will keep running RemainCo and NewCo in line with the long-term strategy, which includes putting money into commercial growth and innovation. Turning to the deal for essentially all of Biotronik's vascular intervention business, also made public on February 27, we still expect to complete it by the close of Q3 of 2025, assuming the usual closing conditions are met, among them getting specific regulatory clearances; we still find that the vascular interventions business fits very well with the legacy Teleflex interventional business. This deal will bring a wide range of therapeutic products into Teleflex's lineup of interventional access products, strengthening our worldwide position in the cath lab. The Biotronik vascular intervention product range dovetails with what Teleflex currently sells in the cath lab. Our present complex PCI portfolio includes items used in challenging coronary interventions, and with the addition of the innovative products we anticipate acquiring, we can push our technology forward with coronary and peripheral interventions that matter. We perceive a major chance to carve out niche markets within coronary intervention; take, for instance, how pairing the recently launched Teleflex Ringer catheter with the PK Papyrus in Biotronik's vascular interventional portfolio would deliver a complete and one-of-a-kind answer for treating vessel perforations both acutely and over the long term during coronary procedures. The worldwide total addressable market for coronary vessel perforation treatment is thought to exceed $80 million. We are likewise enthusiastic about the budding potential in resorbable scaffold technologies and our capacity to broaden the procedure base we currently serve. This vascular intervention business will additionally cement our global footprint in the rapidly expanding peripheral intervention market and open a route for Teleflex products that today carry a peripheral indication. The business we are acquiring rests on solid research and development, clinical know-how, and worldwide manufacturing strength, which we think will further strengthen Teleflex's innovation pipeline and put the company in position to take part in the emerging potential of resorbable scaffold technologies. Those are all the comments I had ready. At this point, I want to hand things over to John, who will walk through our first-quarter financial results in greater detail. John.

John Deren

executive
#4

Thank you, Liam, and good morning to all of you. Following what we already covered regarding the company's revenue results, I'll start off with margins. Adjusted gross margin for the quarter came in at 60.4%, which represents a decline of 70 basis points compared with the same period a year earlier. That year-over-year drop was mainly attributable to ongoing cost inflation tied to macroeconomic factors—particularly labor and raw materials—along with an unfavorable product mix, though cost improvement programs provided a partial offset. In Q1, adjusted operating margin stood at 24.7%. The 190 basis point decline from the prior year was chiefly caused by the flow-through of the gross margin decrease year-over-year, expenses tied to employees, and investments aimed at growing the business. Net interest expense came to $16.6 million in Q1, down from $21 million in the comparable period last year. That year-over-year reduction in net interest expense mirrors lower interest rates as well as reduced debt outstanding. Our adjusted tax rate for Q1 of 2025 was 14.5%, versus 13.2% a year earlier. The rise in our adjusted tax rate compared with last year stems mainly from additional costs resulting from the enactment of the European Pillar Two tax reform. On the bottom line, adjusted earnings per share for Q1 was $2.91, which is a 9.3% decline relative to the prior year. This year-over-year drop in EPS mirrors lower revenue, reduced operating margins as described earlier, foreign exchange, and a higher tax rate compared with last year, partly offset by decreased interest expense and a lower share count. Now I'll shift to a few balance sheet and cash flow highlights. Cash flow from operations in Q1 was $73.3 million, versus $112.8 million in the same period last year. That $39.5 million reduction was mainly due to operating results and unfavorable working capital changes, which were largely the result of inventory purchases and outflows tied to cloud computing arrangements expenditures as part of our ongoing ERP system upgrade. Switching over to the balance sheet: at the close of Q1, our cash and cash equivalents and restricted cash equivalents balance stood at $317.5 million, compared with $327.7 million as of year-end 2024. Net leverage at the end of the quarter was roughly 1.8 times. To wrap up on the quarter, I'll give an update on the $300 million accelerated share repurchase program that we entered into on February 28, 2025. That program finished on April 9, 2025, and we received just over 2.2 million shares of common stock at an average price per share of $135.23. Now I'll move to financial guidance. We still expect 2025 adjusted constant currency revenue growth of 1 to 2%. We now assume a negative foreign exchange impact of $5 million, which represents an approximately 17 basis point headwind to GAAP revenue growth in 2025. That's compared with our previous guidance of approximately $55 million, or a 180 basis point headwind for 2025. The revised foreign exchange guidance assumes an average euro exchange rate of approximately $1.10 for 2025. Due to the foreign exchange outlook, we've raised our 2025 reported revenue growth guidance from between -0.35% and 0.65% up to 1.3%-2.3%, which translates to a dollar range of $3.086 billion-$3.117 billion. When it comes to tariffs, things are still very much in flux and will probably shift in the months ahead. There's still considerable uncertainty regarding where the administration's tariff policy will land, when it will take effect, and how big it will be, plus how other countries might retaliate. Worth noting: if not for the tariffs put in place since we issued our prior guidance, we estimate that our full year 2025 results would land inside the guidance ranges we previously provided. Our present outlook factors in tariffs as they stand right now, which includes the country-specific reciprocal tariff rates that got pushed back by 90 days, but it doesn't account for possible future tariffs that haven't been proposed yet. On the flip side, the 2025 outlook doesn't assume tariffs could be delayed again or lowered. Any shifts down the road could alter the expected hit to our adjusted EPS in 2025; we're anticipating a tariff impact of roughly $55 million in 2025, which will show up in cost of goods sold and is before any future efforts to reduce the exposure on the business. About 50% of the overall tariff impact relates to China. Within that 50%, roughly 80% involves products sold into China, while the remaining 20% comes from imports into the U.S. Beyond that, about 35% of the overall tariff impact relates to Mexico, on products that aren't currently USMCA compliant, at a rate of 25%. We now anticipate 2025 adjusted earnings per share landing between $13.20-$13.60, compared with $13.95-$14.35 before. To be specific, the shifts in our 2025 adjusted earnings per share range came from an estimated $1.05 in headwinds tied to tariffs enacted since we issued our prior guidance, partly offset by a $0.30 benefit — $0.20 of which stems from lower share counts, including the outcome of the recently completed accelerated share repurchase program, with the rest from expense control and a modest foreign exchange benefit. We're actively looking into ways to lessen our tariff exposure in 2025, though these steps will take a while to put in place. More precisely, we're concentrating on optimizing our supply chain, which includes chain of custody changes, boosting our mix of USMCA compliant products — that gives tariff waivers for products assembled in Mexico and Canada using US components — along with ongoing, disciplined control of our spending. We'll also start rolling out higher customer pricing as contracts come up for renewal. In addition, for modeling purposes, here's what you should keep in mind. We now expect 2025 gross margin to land between 58.25%-59%. Roughly 180 basis points of the total 200 basis point cut to gross margin guidance is tied to tariffs, with the rest coming from foreign exchange impacts. We now expect operating margins between 24.6%-25% in 2025. The updated gross margin projections we have are what drive the change in our guidance. Now let's look at the below-the-line items. For 2025, net interest expense should come in at roughly $75 million. On taxes, our guidance is still the same — around 13.5% for 2025. Looking at the whole year, we anticipate diluted share count of about 44.9 million; as for the second quarter, adjusted constant currency growth should land somewhere between 0.5% and 1.5%, and that figure leaves out a roughly $2 million benefit from foreign exchange; that brings my prepared remarks to a close. At this point I'd like to hand the call back over to Liam, who will offer some closing commentary.

Liam Kelly

executive
#5

Thanks, John. To wrap up, I want to run through the main points from our first quarter of 2025. If you set aside the effects of currency, the quarter played out pretty much the way we thought it would. As we went into the quarter, here's what we anticipated: pressure on the OEM business stemming from the loss of a customer contract along with customer inventory management, a drop in the UroLift business tied to the final year of reimbursement phasing, and headwinds from China volume-based procurement. Our expectation remains that these headwinds are transitory, though, as we've said before, they'll amount to roughly a $100 million hit to revenues in 2025. Even as the business deals with the consequences of these idiosyncratic factors, we did see Barrigel keep up its strong growth, with revenue climbing strong double digits during the quarter. Our EZ-IO and OnControl franchise performed well, posting strong growth. Our complex catheter business rose high single digits, and our PICC business hit double-digit growth. Were it not for the tariffs put in place since our prior guidance was issued, we estimate that full year results for 2025 would land inside the guidance ranges we previously stated; we made good on our commitment to return capital to shareholders via our accelerated share repurchase program and keep working toward long-term value creation through a proposed separation of our business into two publicly traded companies, while also pursuing a potential sale of NewCo at the same time. In line with how Teleflex performed in the first quarter and the outlook for 2025, RemainCo constant currency revenue growth matched what we expected. We expect that several of the specific headwinds the business is facing this quarter will be resolved over the coming quarters, and we stay hyper-focused on bringing the business back to growth and creating shareholder value. That brings my prepared remarks to a close. At this point I'd like to hand the call back to the operator for Q&A.

Patrick Wood

executive
#6

Excellent. Thank you very much. Good morning, everyone. Perhaps I could just quickly put a question to both of them right at the start, if that's alright. This is a bit out of left field, but with all the chatter about supply chains and so on, have you noticed any additional demand, I suppose, coming from the OEM part of the business? Even just early conversations in which folks are considering onshoring and relocating their supply chains. It sounds like you two could serve as a solution provider in that regard; and then, just very briefly, as a follow-up, when it comes to Biotronik and completing that deal, the vascular piece, do you feel you'd want to keep expanding it over a longer horizon, possibly through other assets? What I mean is, vascular strikes me as a space that gets overlooked fairly often by some of the bigger strategics, so it does look like a possible chance to continue growing there. How much of this, beyond simply Biotronik, represents a sustainable area of focus for you both? Thanks.

Liam Kelly

executive
#7

Thanks, Patrick, and good morning to you too. I'll begin with the first portion of your question, the supply chain; within OEM, we've observed demand strengthening. Throughout the quarter, we continued to see the order rate get better. Whether that ties back to what's happening in the supply chain, I can't say for certain, since it would be premature for that to have occurred. My sense is that this reflects base demand; as anticipated, we did experience an impact of roughly $7 million related to vertical integration in OEM. We also observed destocking during the first 2 months of the quarter. As the quarter progressed, demand within the OEM business picked up. Hearing that was pretty uplifting, and it makes us feel good about OEM hitting its targets across the entire year. As for what you asked regarding Biotronik and putting money specifically into that Cath Lab call point, that's definitely going to be something Teleflex and RemainCo concentrate on. I'd add that while we're in this interim period, we'll be concentrating on integrating Biotronik into Teleflex, and we'll keep our attention on the two-track approach we just made public — spinning off NewCo while simultaneously pursuing a sale process driven by the interest that's come in. Thanks to our larger footprint and stronger presence in the Cath Lab, we expect to generate roughly $1 billion in revenue there, and that will serve as a strategic call point for Teleflex. Turning to a broader remark about the quarter, Patrick — I'd say the quarter unfolded in a way we found pleasing; things went very much according to what we had anticipated. Our execution was fairly strong. Revenue landed right where we expected it to land. Clearly, we stayed on track with our margin profile and our earnings profile. The ASR did better than expected. In our view, it was a solid beginning to the year for Teleflex. Thank you.

Michael Sarcone

analyst
#8

Morning, everyone; Mike here filling in for Matt today. Appreciate you taking our questions. To kick things off, regarding the tariffs, you brought up $55 million, and that figure comes before any mitigation efforts. Could you provide a bit more detail? I recall you touched on a few points about how fast near-term mitigation strategies could realistically be put in place and what sort of EPS headwind they might offset if executed efficiently.

John Deren

executive
#9

I'll handle that one. Clearly, the tariff landscape as it stands is disappointing. That $55 million reflects what has been enacted as of now and, as I said, excludes any mitigation strategies. Here's the thing — we've already taken several steps in advance of the tariffs. We shifted inventory ahead of them; we brought supply into China before the tariff increase took effect. Right now we're ensuring inventories sit in the regions by sending them to bonded warehouses, where no tariffs apply, so that once conditions ease, we can move product into the country quickly. As for other mitigation strategies — and there are several, some requiring more time than others — I'd say the primary focus at the moment is a close examination of the USMCA exemptions in Mexico. Roughly 50% of our inventory currently qualifies for exemption under USMCA, and there are genuine opportunities to bring far more of that inventory under the exemption. It won't be uniform — timing differs by product, since you essentially need 90% of components sourced from the U.S. It will vary, but we're confident we can raise that share substantially. I don't think we're ready to give a target that would get you to a revised EPS figure, but that's our first initiative. We're also examining supply chain opportunities to shift where we source product and sidestep the tariffs. That work is already in progress and could take somewhat longer. There are multiple strategies to mitigate. Finally, we're exploring chances to raise prices if the tariffs persist — opportunistically as contracts come up for renewal and in areas where we aren't under contract, more immediately. We've established a tariff council that's closely monitoring supply chain opportunities, and we also hold a regular commercial meeting focused on pricing. Many things, many strategies to mitigate the tariffs. Again, that 55 doesn't account for any of it. It's purely the calculation of what exists today. I see it as worst case. Hopefully no further negative policy shifts occur, and once again, there will be chances for us to mitigate these further.

Liam Kelly

executive
#10

Mike, let me just tack on one remark to what John said. This is something already put into action and reflected in our guidance, but we've put some deliberate controls on spending in place, and that makes up part of the $0.30 offset John referred to during his prepared remarks, which is counterbalancing the tariff effect. There are several mitigations — a number already active, with others we'll bring in as the rest of the year unfolds.

Michael Sarcone

analyst
#11

Understood. Thanks a lot. That's genuinely useful. As a quick follow-up, because you brought up pricing, we're curious about how you see Teleflex's current position when it comes to possibly pricing more aggressively. On the recontracting side, could you share any indication of whether certain business areas or segments see a bigger effect from that? We're simply trying to gauge roughly how many of those contracts can be renegotiated soon.

Liam Kelly

executive
#12

Sure. Within the U.S., when you factor in our GPOs along with our large IDNs, over 50% of our business sits under contract there. What we'll be undertaking across the coming 2 quarters — and some of this work has already started — is that we're starting with the non-contracted portion, and we're pinpointing products in that non-contracted portion that tariffs are hitting. Should those tariffs remain, pricing adjustments will be rolled out on such products. During 2025, whether you look at Q1 or the entire year, we intend to raise pricing by 30 to 50 basis points, and should these tariffs remain, our intention is to speed that up, with further updates provided as each quarter passes.

Jayson Bedford

analyst
#13

Morning, everyone. I appreciate the thorough breakdown. Regarding what you said about notable interest from other parties in NewCo — are you thinking about, or open to, selling off portions of NewCo, or do you intend to spin off or sell the whole NewCo portfolio in the way you described?

Liam Kelly

executive
#14

Yes. Morning, Jason. To start, I'd say the volume and caliber of inbound interest we've gotten in NewCo has us feeling quite positive. Shareholder value creation will be our guiding principle. Given how much interest there is, we think this process will be competitive, so we're feeling fairly bullish about our capacity to drive shareholder value via this parallel process of spin and sale. Jayson, it is a parallel process. We're still moving forward with the spin-related activities, while also engaging with companies regarding the sale. As for that part of your question — would we sell parts? Whatever delivers the greatest value for our shareholders is what we'll do. With the aim of unlocking that shareholder value, we're clearly open to exploring every option.

Jayson Bedford

analyst
#15

All right, that's useful. And perhaps directed at John — regarding that $55 million tied to tariffs, does that represent the effect across 2 quarters?

John Deren

executive
#16

Yes; capitalized variances apply here, and it will initially be recorded in inventory. During Q2, there won't be any effect on the P&L. Effects will begin in Q3 and Q4. At this point I won't break down specifics by quarter, but you ought not to anticipate it being somewhat heavier in Q4, when the bulk of the effect lands.

Liam Kelly

executive
#17

Alright. Vik, I appreciate the question. And good morning to you too. What I’d say is that I don’t have a preference between a sale or a spin. As I mentioned before, what guides us is generating and releasing value for shareholders. In truth, from many angles, we view this as confirmation of how solid and valuable the SpinCo assets are. With the volume of inbound interest we’ve received, for us, this matches what we anticipated. When we made the spin announcement, we did anticipate receiving inbound interest. In full transparency, the degree and the caliber of that inbound interest is actually exceeding what we had anticipated, and that’s quite encouraging. We are firmly pursuing a dual track of both spinning and selling, and what will guide us is maximizing shareholder value as we move along that dual track. Honestly, Vik, it’s somewhat early to discuss timing. We’ll work both tracks in parallel, and we’ll keep the investment community informed whenever we have updates. Understood. That helps. Thanks. My follow-up, Liam, is that the market didn’t respond well to the deal or to the separation. Thinking back to your Q4 earnings call, perhaps you could just address what the screen is failing to see. Thank you. Yeah. Regarding the Biotronik deal, we view it as a highly attractive asset, and we intend to close the acquisition at the end of Q3 ; we still expect it to contribute roughly EUR 91 million in Q4. I don’t believe the screen is overlooking anything concerning Biotronik, but I don’t really think they grasp which assets sit inside the Biotronik portfolio; in our prepared remarks today, we provided just one small illustration of how combining PK Papyrus with the Ringer catheter will in fact establish a niche in the Cath Lab for perforations that these combination products will in fact control within that space. It’s an excellent fit for Teleflex. This company generates 50% of its revenues in EMEA. Combining the Teleflex channel across the Americas with the Biotronik channel in EMEA will in fact improve access to the Cath Lab; they possess outstanding R&D capabilities and that Cath Lab presence, as I mentioned. Naturally, we have the option of Freesolve, the resorbable scaffold possibility, which aligns closely with the existing direction in interventional cardiology procedures of leaving nothing behind. It gives the cardiologist flexibility for additional procedures with that patient using a fully biosorbable scaffold capable of addressing the patient’s issues. I believe there are numerous appealing elements among the Biotronik assets. Once it joins the Teleflex family, we’ll be able to discuss more about the components of the product categories contained in the Biotronik portfolio. There are several truly meaningful ones, like drug-coated balloons, the peripheral Passeo drug-coated balloon. A number of them have been expanding at a double-digit CAGR across recent years. In my view, this one's margin and growth characteristics align extremely well with Teleflex and cement our position more firmly in that Cath Lab.

Matthew O'Brien

analyst
#18

All right. Thank you very much, and I'm grateful that you're fielding these questions. Liam, regarding this morning's update on the substantial interest in the spin or NewCo, I have a couple of things to ask. Here's the first, and in a moment I'll pose the second. On that first one, I realize you're not keen on revealing too much, but in the present climate, it's hard for me to picture many strategics being ready to step out and pursue transactions at this point. Would it be reasonable to assume that most of the inbound interest thus far has come from the financial sponsor community, or is the blend of strategics better than you'd have expected? I do have that follow-up.

Liam Kelly

executive
#19

Yeah, Matt. Thanks. That's a good question. In fact, what we received was a healthy combination of interest coming inbound from both strategics and private equity. As I mentioned a moment ago, the interest exceeded what we'd expected, and I'd view it as a strong validation of the quality of the assets held within NewCo. Both is the straightforward response to what you asked.

Matthew O'Brien

analyst
#20

Understood. All right, thanks for that. If I examine the assets being separated, you're spending a bit more than $1 billion on NeoTract, and roughly $600 million on Palette. Combine those with OEM and acute care. My guess is that the total worth of all those pieces would come to around $2 billion. So how should we approach the valuation from this point? Do the amounts you paid for those two assets serve as a solid starting reference, or not?

Liam Kelly

executive
#21

Matt, once more, I appreciate the question. I won't discuss valuations during this call. My view is that this is a matter we'll address as we evaluate the inbound interest. From a valuation standpoint, what we'll likely do is draw a comparison to how these NewCo entities would be priced in the equity market. We'll factor in the tax leakage, and we'll act in whatever way benefits our shareholders most. Since the beginning, our entire aim has been to maximize shareholder value and shareholder returns; that guiding principle will decide which branch of the parallel path we take, and it will serve as our North Star.

Anthony Petrone

analyst
#22

Appreciate you squeezing us in. Perhaps returning to the subject of tariffs — I'm curious how that $55 million gets divided between RemainCo and SpinCo, or the sale here, and how you plan to sort of handle mitigation across both entities as we head into the back half of the year, plus one quick follow-up.

Liam Kelly

executive
#23

Anthony, I'll have John take that one, though I'll say this: right now we operate Teleflex as a single Teleflex, and the split won't happen until mid-2026. John.

John Deren

executive
#24

I believe you've already covered that, Liam. What I mean is, we aren't going to discuss anything past 2025 when it comes to tariffs. That would be way too speculative given how fast policy shifts happen. As we continue developing those mitigation strategies, both companies will certainly feel the effects. I think once we get nearer to a full spin, we'll say a bit more about how the two companies shape up and what tariff effects exist at that point.

Anthony Petrone

analyst
#25

Perhaps a quick follow-up regarding Biotronik. If you're able, dig a bit deeper into the specifics on initial perspectives concerning cost synergy, and revenue synergy too, whether broken out by product category or by geography. Thanks once more, and it was great to reconnect with everybody. Thank you.

Liam Kelly

executive
#26

Yes. Thank you, Anthony. Like I mentioned previously, Anthony, the channel is what this is entirely about. My view is that when you consider the chance that exists to utilize the Biotronik channel throughout Europe so that additional Teleflex products move through it, and afterward utilize the Teleflex channel across the Americas so as to utilize the Biotronik portfolio, I believe that represents the essential metric. Clearly, we will be examining possibilities for going direct in the OUS regions. This is a truly attractive asset that we are going to bring into the organization. 70% of the revenues in the current respect, which we know and love incredibly well. Like I mentioned previously, they possess some genuinely outstanding products. We are going to fund the R&D at Biotronik so these inventive products keep advancing. We are going to carry on with the clinical study on Freesolve so that it reaches the market. That is a wonderful option that arrives alongside Biotronik to generate revenue growth down the road. Plenty of positive things regarding Biotronik from where we sit.

Shagun Singh

analyst
#27

Thanks. Appreciate you fielding this. Regarding the interest in NewCo, could you tell us whether it applies to just certain units or to the whole operation? On the separation, mid-2026 still sounds like the goal. Can you update us on how things are progressing there? Might you be able to provide additional specifics? I have one more question after this.

Liam Kelly

executive
#28

All right. Shagun, most of that interest covers all of NewCo. Things are still at an early stage. The spin was announced just 2 months back. Like I've mentioned a few times, I'm quite encouraged, not just by how many inbounds there are, but by their quality. On the spin, the search for executive management has begun, and our plan is to file our Form 10 during 2026. In our view, nothing about the timing has shifted, and we keep working toward those dates.

Shagun Singh

analyst
#29

Understood. Liam, I'd like to hear your latest perspective regarding how NewCo and RemainCo will grow. When I review the quarter, it strikes me as somewhat uneven, particularly since the NewCo assets are posting a decline. You mentioned certain headwinds during the call, which I appreciate. What's your thinking on that low single-digit ex-FX growth figure for NewCo? Could RemainCo reach growth of 6% or more? Thanks for taking my question.

Liam Kelly

executive
#30

Thank you, Shagun. Just as total Teleflex results met expectations, so did results at both RemainCo and NewCo, with all of it matching what we had anticipated. Clearly, Q1 represents the biggest decline for OEM, which makes up a substantial portion of NewCo. Conditions will get better by the latter half of the year. There's the effect from the last customer, amounting to $7 million per quarter across Q1 and Q2. That laps as we enter Q3. As I mentioned in my prepared comments and in a response earlier, OEM's order rate improved considerably over the course of the quarter. That's quite encouraging. Everything has unfolded as we anticipated, Shagun, whether for NewCo, RemainCo, or TeleflexCo, and we're carrying out that plan for the year. One thing to keep in mind, everyone: the separation happens in mid-2026. We're now running on a parallel track, and we'll keep bringing you updates. Our guiding principle — and I need to say this once more, likely for the fifth time — our guiding principle is to unlock the greatest possible shareholder value throughout this parallel process.

Richard Newitter

analyst
#31

Hello, and thank you for allowing me the question. I have a few quick follow-ups regarding the tariff. I believe you stated that you anticipate conditions in China will improve as the year progresses. What I want to ask is more about the fundamental growth trajectory in the aftermath of the trade conflict. If I understood that point correctly, what is the basis for your optimism that China will improve as the year goes on? Then, regarding the $100 million tied to the underlying China headwind, are there any items on the list of potentially exempted devices that people have been speculating about that you could qualify for? I am also curious whether, with Biotronik, any EU manufacturing and the 10% baseline are part of the $55 million you identified for tariffs.

Liam Kelly

executive
#32

Thank you. All right. Everyone, that covers a great deal. I will begin with China. The reason we expect a better revenue environment there is volume-based procurement. For any volume-based procurement, the biggest effect you would observe comes at the point of destocking. In addition, we face some difficult comparisons in the balloon pump business in Q1 in China. From a growth standpoint, we would view this as the low point for APAC, and we would expect APAC to improve from here onward, with China improving for that same reason. As for exempt devices, we hold out hope that medical devices will be left out. Even if — we do not produce in China and bring into the United States — but a new iPhone is not something I require. When you are in a hospital bed, medical devices are what you require. I believe we must be thoughtful about exemptions for specific products. To me, medical devices appear to be a category necessary to keep people alive both in China and in the United States. We hope that common sense will win out as this process unfolds. On your Biotronik question, the effect of tariffs on Biotronik, simply given their revenue profile, is de minimis. I believe that addresses every aspect of what you asked, Rich.

Craig Bijou

analyst
#33

Morning, everyone. Appreciate you letting us ask. I'd like to begin on the urology segment, interventional urology. Results landed slightly above what had been anticipated. I realize you mentioned there are still certain pressures affecting UroLift, particularly at in-office locations. Liam, I was hoping you might discuss how Barrigel is performing and whether it's on track for that roughly 20% expansion you had projected. Has there been any easing for UroLift in the office setting, understanding that a challenge probably remains — but is there any easing there? Yeah.

Liam Kelly

executive
#34

Thank you, Craig. On our end, interventional urology matched what we had forecast; performance was on plan. Regarding the second part of what you asked, Barrigel keeps delivering remarkably strong results, expanding at a robust double-digit rate and carrying forward the momentum achieved during the prior year. With UroLift, we recorded healthy double-digit expansion across APAC. We kept making inroads into that region. The office channel here in the United States, Craig, remains quite difficult. We did notice some modest strain on the hospital portion of the business; this marks the final year of the reimbursement adjustment; our hope is that after this concluding year of reimbursement changes is behind us, we will start observing some gains for UroLift across the different sites of service. The AUA conference took place only this past weekend. I was there in person, and plenty of excitement surrounded both the Palette business and UroLift. In my view, the team performed well at that event.

Craig Bijou

analyst
#35

Thanks, Liam. I wanted to ask a follow-up regarding the balloon pump situation — is there anything new you can share about what hospitals are telling you, especially in light of the competitor's quality problems?

Liam Kelly

executive
#36

Yes, Craig. Things are exactly where they were, and exactly where we anticipated. During our prepared remarks, we mentioned that North America delivered strong growth in the double digits. APAC faced a tougher comparison. Quotations during Q1 were once again solid. It's encouraging that folks continue coming forward seeking an increasing number of quotes for the product. Our outlook for the balloon pump business remains unchanged. Thank you.

Mike Polark

analyst
#37

Morning, and thanks for taking the question. Regarding the second quarter, I caught the guidance calling for TFX revenue growth of 50 to 150 basis points, but I didn't pick up anything regarding earnings. Given all the various pieces in motion, I'd like to know whether you'd be open to laying out some sort of 2Q EPS expectation, or the puts and takes we should factor in there.

Liam Kelly

executive
#38

Mike, on a quarterly basis we don't provide EPS guidance — revenue is what we guide to. To assist with your modeling, though, that guide points to a revenue range of $769 million to $777 million, which works out to the percentages you laid out.

Mike Polark

analyst
#39

On the OEM follow-up, I've taken in everything that was said. Even if we set aside that $7 million contract loss, a $17 million decline versus a year ago strikes me as a sizable figure where inventory management is concerned. I also picked up that order trends are getting better as the quarter progresses. Is there anything more you can point to? What I mean is, customer concentration in this line of business, and product concentration too, isn't something I'm especially fond of. Inventory management pressures, in my view, are the sort of thing that would normally arrive gradually across a longer stretch, so having them all erupt in a single Q caught me off guard. What additional detail can you offer so I can make sense of it? Thank you.

Liam Kelly

executive
#40

Yeah, Mike. What I'd say is that this matches our expectations. For the OEM business, this is precisely what we anticipated; the OEM business will bottom out here. As the year unfolds, you'll observe sequential improvement. That's right. Order rates genuinely started to climb during the later portion of the quarter. That's a positive sign. I believe you're also right about this. There's a $7 million effect tied to that vertical integration, and it landed in Q1. It will show up once more in Q2. We continue to anticipate some inventory management in Q2. After that point, the worst of the inventory management is behind us. I realize that from an external vantage point it likely appears heavier in Q1, yet from where we sit internally, this is precisely what we anticipated. OEM met their plan. When you receive orders, keep in mind that you book an order, but that order then begins flowing through the income statement during the back half of the year and on into 2026. In my view, the team is performing well in OEM. In my view, they possess a solid, robust platform of new business that they're developing. In my view, we're in good shape with OEM. The investment community will see it clearly as the year progresses and that sequential improvement starts to appear.

Mike Matson

analyst
#41

Yeah. Thanks. I just wanted to ask about a couple of products that I don't believe you've brought up yet. MANTA and Standard Bariatrics — maybe you could give us a quick update on those. Is it fair to assume they're still adding to your growth?

Liam Kelly

executive
#42

Yeah. MANTA keeps gaining ground in the large bore market. When it comes to Standard Bariatrics, because of the deductible impact, it typically has a very heavy Q4 and a somewhat lighter Q1, and then it builds as the year progresses. Both are where we would have anticipated, and both are performing well. One thing worth noting, Mike, on the high-growth portfolio, is Intraosseous. Intraosseous had a really strong quarter one. The hemostatic portfolio also did well within that group. Yeah, we didn't get into a lot of detail on them since they're doing as one would expect. Thanks for the question.

Mike Matson

analyst
#43

All right, thank you. Now regarding the effect of tariffs — that $55 million — if we wanted to turn it into a figure for a full year, it seems likely that it would be somewhat greater than twice that amount. Is that a reasonable assumption, simply because the pressure is intensifying toward the end of the year?

Liam Kelly

executive
#44

Once more, attempting to provide a full-year figure would mean we're jumping ahead of where we are. I'd advise avoiding any attempt to determine that, in light of how conditions keep shifting and what we think is our continued capacity to offset this.

Lawrence Keusch

executive
#45

Appreciate that, Amy. And thanks to all of you who took the time to be with us on today's call; that wraps up the Teleflex Incorporated Q1 2025 earnings conference call.

Operator

operator
#46

You may now disconnect your lines.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Teleflex Incorporated transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to Teleflex Incorporated earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Teleflex Incorporated or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.